Logo
T

Tune Therapeutics

91 employees

The vast majority of human disease is governed by the epigenome, the subtle machinery that controls the volume of gene expression in cells. Tune Therapeutics is pioneering the creation of epi-therapeutic medicines with its powerful and precise epigenomic control platform, TEMPO. Unlike genome editing, TEMPO dials the volume of gene expression up or down towards healthy levels, without breaking or permanently rewriting DNA – and it can do this in multiple genes at once. This genetic tuning approach allows us to change cell fate and function at will, unlocking the ability to reverse pathways of cancer, genetic disease and aging. Our approach effectively expands the potential reach of genetic medicine – from targeting a limited range of rare conditions, to overcoming thousands of complex and chronic diseases that currently have no curative treatment.

Investor insights

Funding rounds participated in

$175M sweet spot round size

Investor type

Privately Held

Basic info

Industry

Biotechnology

Sectors

Biotechnology

Date founded

2020

Funding rounds raised

Total raised

$175M

from 3 investors over 1 rounds

T

Tune Therapeutics raised $175M on February 12, 2025

Investors: Regeneron Ventures, Yosemite and + 2 Other investors

FAQ